Posted March 13, 2015

Weight Supplement Containing Drugs Recalled

On March 10, 2015, UltraZx, Labs, L.L.C, issued a voluntary recall of all lots of weight loss supplement UltraZx because it was found to contain undeclared sibutramine and phenolphthalein.

Sibutramine, the active ingredient in the obesity drug Meridia, was removed from the U.S. market in October 2010 because it can substantially increase blood pressure and pulse rate in some individuals, and may present a significant risk for patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke. This drug may also interact, in life-threatening ways, with other medications a consumer may be taking.

Phenolphthalein, once an ingredient in some over-the-counter laxative products, was reclassified by the FDA in 1999 as "not generally recognized as safe and effective." Recalled UltraZx is packaged in bottles containing thirty 300 mg capsules, and was distributed between September 2014 and February 2015.

Consumers who have purchased UltraZx should not use it, but return the product to UltraZx Labs, and contact their healthcare provider if they have experienced any adverse side effects. Consumers and healthcare providers are also encouraged to report any adverse reactions to the FDA's MedWatch Adverse Event Reporting Program.

See ConsumerLab.com's Review of Weight Loss Supplements for tests of related products.

See Related Warnings:

Five Weight Loss Supplements Recalled

Weight Loss Supplement Contains Hidden Drug

FDA Warns of Weight Loss Supplement Dangers

FDA Warns Consumers Not to Buy or Use Weight Loss Supplement

Weight Loss Supplements Recalled

FDA Warns Some Bee Pollen Products for Weight Loss Are Dangerous

Bee Pollen and Weight Loss Supplements Recalled

FDA Warns Consumers Not To Buy Or Use Weight Loss Supplement

Recall of "Bee Pollen" Supplement Found to Contain Drug

FDA Warns Consumers of Weight Loss and Body Reshaping Supplements Containing Controlled Substance

For more about this recall, use the link below.